The Wellness Solution Review: What Its GLP-1 Documentation Establishes—and What It Does Not

The Wellness Solution offers an important distinction for anyone evaluating GLP-1 advertising: evidence that a company offers access to treatment is not evidence that its particular treatment produces the results associated with a clinical trial. Its public pages describe semaglutide, tirzepatide and a GLP-1 Microdose program, alongside hormone and peptide services. They also describe clinical review, partner pharmacies and follow-up. Those documents establish a service proposition—not independently measured effectiveness, verified professional credentials or the performance of a particular compounded preparation.

This review examines public documentation consulted October 19, 2026, with that boundary in mind. The platform advertises plans starting at $146 per month, subject to provider review, but does not connect that minimum to a particular medicine or supply. More consequentially, its cancellation, geographic-coverage and privacy statements need to be read together rather than in isolation. The useful question is not simply whether GLP-1 medicines have research behind them, but which parts of that research—and which service promises—actually describe what this platform offers.

At a glance

Business structure: Ceifaa Health System Inc operates the website; the platform says independent practitioners make clinical and prescribing decisions.
Sources: [9] [10]
Starting price: Plans are advertised from $146 per month, confirmed after provider review; the minimum is not tied to a specific drug, quantity or supply period.
Sources: [10]
Compounded treatment: The treatment page includes medication prepared by partner compounding pharmacies; compounded preparations are not FDA approved.
Sources: [6] [1]
Cancellation conflict: Terms specify turning off auto-refill at least 48 hours before processing, while treatment FAQs require 30 days’ notice before the next billing cycle.
Sources: [9] [6]
Geographic limits: Despite nationwide marketing, terms restrict service to operating states and require the patient’s consultation location to match the account’s shipping state.
Sources: [10] [9]

Start with the product, not the ingredient’s reputation

The Wellness Solution’s semaglutide page describes a supervised program involving a weekly injection and home delivery. Its tirzepatide page advertises a provider-directed dual GLP-1/GIP program with flat-rate pricing, but the consulted description does not specify the administration route. These are meaningful differences in documentation. An ingredient name alone does not establish the finished preparation, concentration, presentation, supply quantity or evidence applicable to the product a patient would receive.

The treatment page explicitly includes compounded medication prepared by partner compounding pharmacies. The homepage also acknowledges that compounded medications are not FDA approved and that FDA has not independently verified their safety, effectiveness and quality. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That recommendation should inform the prescribing conversation; it is not a categorical conclusion about this company’s legality or quality.

Nonapproval alone does not establish clinical inequivalence, either. The appropriate next step is to identify the actual preparation and why it is being proposed, rather than assuming it is interchangeable with a studied product—or dismissing it solely because it is compounded. Our explanation of approved and compounded treatment evidence separates those questions. The consulted documentation does not identify the dispensing pharmacies by name, so their credentials and product-specific practices could not be independently assessed here.

What the documented offerings establish
Offering	Documented description	Important remaining question
Semaglutide	Weekly injection within a supervised program	Which preparation, concentration and quantity would be prescribed?
Tirzepatide	Provider-directed GLP-1/GIP program with flat-rate pricing	What route and presentation are offered?
GLP-1 Microdose	Lower-dose program marketed for metabolic health and body composition	Which ingredient and route are used, and what evidence supports the protocol?
Hormone services	Bloodwork- and symptom-based care for men and women	Which tests and services are included in the quoted price?
Peptide services	Provider-reviewed therapies compounded in a U.S. pharmacy	Which products, prices and product-specific evidence apply?

Sources: [6] [5] [10] [1]

Microdose marketing needs its own evidence

The GLP-1 Microdose program is marketed for metabolic health, body composition and appetite recalibration rather than aggressive weight loss. Its listed candidate groups include people at or near their goal weight and people who poorly tolerated standard GLP-1 dosing. Those are the provider’s positioning statements, not established benefits or individualized eligibility findings. The consulted description does not identify the specific ingredient or administration route, making the protocol difficult to evaluate beyond its marketing category.

Research on a named medicine does not automatically validate a lower-dose program with a different purpose. STEP 1 and SURMOUNT-1 studied defined treatments in defined populations; they did not measure outcomes from The Wellness Solution or establish the effectiveness of its Microdose offering. This review therefore does not borrow trial weight-loss percentages to fill the documentation gap. The distinction is explained further in why a trial is not a provider performance report.

The broader business also advertises hormone optimization for men and women, based on bloodwork and symptoms, with continuing monitoring and adjustments. Separately, it promotes provider-reviewed peptide therapies compounded in a U.S. pharmacy for recovery, metabolism, longevity and focus. The consulted advertisement does not identify those peptide products or prices. Neither the breadth of the menu nor the presence of clinician review independently establishes the benefits of each advertised intervention.

Sources: [11] [10] [3] [4]

Who provides care, and what enrollment actually requires

The terms identify Ceifaa Health System Inc as the website’s owner and operator. The brand describes itself as a concierge telehealth platform facilitating access to independent, U.S. board-certified clinical providers and state-licensed compounding pharmacies. Those credentials are website claims, not credentials independently verified for this review. The platform expressly says it does not practice medicine, write prescriptions or dispense pharmaceuticals. Clinical evaluations and prescribing decisions are assigned to independent licensed practitioners.

Enrollment requires registration and an account with a username and password. The advertised process begins with health questions in a secure online form, followed by a licensed provider’s assessment of whether online treatment is appropriate. The terms are more explicit about the prescribing threshold: a patient must complete a consultation, the provider must determine that the prescription product is appropriate, and a prescription must be issued. Completing an assessment or paying does not establish that medication will be prescribed.

The homepage advertises provider review within one business day and a $0 charge if a person is not approved. That is a stated review and pricing policy, not a promise of medication delivery within one day. The consulted documentation does not name the treating clinicians or medical groups, and it does not establish the precise consultation format. Before enrollment, identifying who handles medical questions, prescribing decisions and pharmacy concerns would make the platform’s division of responsibilities more concrete.

Sources: [9] [10]

Eligibility language and nationwide advertising have limits

The semaglutide page lists adults 18 or older with a BMI of at least 27, or at least 25 with weight-related conditions, as a candidate profile. These are the provider’s published screening criteria, not automatic approval or a general prescribing standard. NIDDK describes general adult pharmacotherapy thresholds of BMI 30 or higher, or 27 or higher with weight-related health problems. The difference is a reason to ask the clinician which product and clinical rationale apply—not to self-determine eligibility.

Published semaglutide exclusions include a personal or family history of medullary thyroid carcinoma or MEN 2; pregnancy, breastfeeding or plans for pregnancy; active pancreatitis; and untreated severe gastrointestinal disease. The platform’s terms separately require users to be at least 18, or the local age of majority if higher. These statements document the provider’s boundaries, but they are not a complete individualized risk assessment or proof that everyone outside the listed exclusions will qualify.

Geography is similarly narrower than the homepage phrase “Telehealth nationwide” suggests. The terms limit service to states where the company operates and require patients to be physically in the same state as their account’s shipping address during consultation. The contact page says operations are in states where the service is licensed, without enumerating them. No concrete state-by-state or product-by-state availability list was established from the consulted pages, so availability needs confirmation before relying on the national advertising.

Sources: [6] [9] [7] [10] [2]

The $146 headline is not a product-specific quote

The homepage advertises plans from $146 per month, labels the figure an educational estimate and says it is confirmed after provider review. It does not establish which medicine, formulation, quantity or supply period qualifies for that minimum. The number should therefore remain visible but narrowly interpreted: it is an advertised starting point, not a confirmed semaglutide or tirzepatide price. No introductory-versus-renewal schedule, multimonth discount or upfront-payment alternative was established in the consulted documentation.

Program FAQs advertise flat-rate pricing without hidden fees, consultation charges or dose-change surcharges. The terms describe a bundled price, when applicable, encompassing the pharmacy’s prescription-drug fee, the medical group’s provider-service fee and the platform-access fee. That is useful detail about the payment structure. However, the documentation does not clearly establish whether laboratory testing, administration supplies or outside services are included. A written quote should distinguish those unresolved items from the inclusions the provider expressly promises.

For a recurring monthly order, the terms authorize an immediate charge and subsequent charges every 30 days until cancellation, with electronic notice five to seven days before a scheduled transaction. That is a 30-day billing interval, not necessarily the same date each calendar month, and it does not establish the medication quantity supplied. “No insurance required” means insurance is not necessary; it does not establish insurance billing, reimbursement support or coverage. The actual charge and fulfillment details need confirmation together.

Sources: [10] [6] [9]

Cancellation is the clearest unresolved policy conflict

Three cancellation statements appear across the public documentation. The homepage says “Cancel anytime.” The terms describe canceling by turning off auto-refill in the user portal at least 48 hours before the applicable monthly processing date. Treatment FAQs instead require 30 days’ notice before the next billing cycle. These are materially different deadlines. The broad homepage phrase does not resolve which operational cutoff a patient will encounter, and this review cannot determine which statement would govern an individual transaction.

The practical issue is whether a cancellation request prevents the next charge or takes effect later. Before starting a recurring order, request written confirmation of the applicable notice period, processing date, cancellation method and effective date. The five-to-seven-day transaction notice described in the terms is not a substitute for resolving the separate 30-day FAQ requirement. Keeping a portal confirmation or written response would document the request without assuming that a marketing phrase overrides more detailed conditions.

Cancellation also must not be confused with a refund. Treatment pages state that consultations, medical visits and fulfilled prescriptions are nonrefundable once services begin or medication is processed. That boundary can matter even when future renewals are successfully stopped. The consulted terms contain an omitted passage, so contractual conclusions here are limited to the visible text. The evidence supports flagging the conflict and seeking clarification, not inventing a more generous cancellation or refund policy.

Sources: [10] [9] [6]

Pharmacy fulfillment and follow-up need separate scrutiny

The terms require prescriptions to be filled through pharmacies accessible through the platform and say purchasers waive their choice of another pharmacy for the included prescription. The applicable pharmacy ships directly to the patient. Treatment pages describe structured shipment timing, temperature-controlled unmarked packaging and direct delivery; the homepage advertises free two-to-three-day shipping. None of those statements establishes the interval from approval to dispatch or guarantees arrival a fixed number of days after the initial assessment.

The terms also warn that prescriptions will not be dispensed in child-resistant containers. That is a material packaging disclosure, separate from whether the shipment is discreet or temperature controlled. If an injectable GLP-1 product arrives warm or inadequately refrigerated, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. A cold-chain marketing claim does not replace resolving a questionable delivery. Our guide to reading delivery and cold-chain claims explains this distinction.

For continuing care, the treatment page includes direct provider messaging through the secure portal between scheduled check-ins, plus structured reviews intended to adjust care to the patient’s response. It does not specify how frequently those reviews occur or a guaranteed clinician-message response time. Those details matter because follow-up concerns tolerability and treatment response, not just payment renewal. The platform’s advertised access is useful, but the public description does not establish a complete monitoring schedule or urgent-care pathway.

Sources: [9] [6] [10] [1] [2]

Privacy and support promises require their qualifiers

Treatment FAQs say medical information is shared only with the assigned provider and dispensing pharmacy, followed by a broad promise never to sell or share data. The California privacy notice adds an important qualification: certain personal information may be made available to third parties for advertising delivery, measurement and improvement, and those disclosures may count as a sale or sharing under California law. That does not establish that medical records are sold, but it limits an unqualified reading of the marketing promise.

The terms also say Ceifaa is not a HIPAA covered entity, although it may act as a business associate of a pharmacy or medical group in some circumstances. This helps explain why a general HIPAA marketing statement is not a complete account of every data relationship. It is not an independent compliance assessment. Readers comparing the documents can use our guide to what public provider documentation can prove to separate stated policies from verified operational practices.

For direct clarification, the contact page lists info@wellnesssolutionrx.com and (470) 284-0204, with clinical hours Monday through Friday, 9 a.m. to 5 p.m.; no time zone is specified. It advertises a contact-form response within 24 hours, distinct from clinical review or shipping. The terms give a mailing address at 2090 Sugarloaf Parkway, Suite 215, Lawrenceville, GA 30045. That address does not establish an in-person clinic, and the documentation does not establish Spanish-language care or interpretation.

Sources: [9] [6] [8] [7]

Questions & answers

Is The Wellness Solution itself the prescriber or pharmacy?

Its documentation says no. Ceifaa operates the platform, while independent licensed practitioners evaluate patients and make prescription decisions, and partner pharmacies fulfill prescriptions. The site’s professional and pharmacy credential descriptions were not independently verified here. Ask for the treating clinician, medical group and dispensing pharmacy names before assuming that the platform’s brand identifies the entities responsible for clinical care.

Sources: [10] [9]

Can I obtain semaglutide for $146 per month?

The consulted pages do not establish that. The $146 figure is a starting monthly estimate, confirmed after provider review, without a specified medicine, formulation or supply quantity. Program pages promise flat-rate pricing and no consultation or dose-change surcharges. Request the actual product-specific quote, billing interval, supply details and any laboratory or administration-supply costs before treating the advertised minimum as your expected payment.

Sources: [10] [6] [9]

Does the Microdose program have the same evidence as standard GLP-1 treatment?

That equivalence is not established. The program is marketed for metabolic health and body composition, but its consulted description does not identify the ingredient or route. STEP 1 and SURMOUNT-1 do not establish outcomes for this platform’s Microdose protocol. Ask which exact preparation is proposed and what evidence supports that specific use, rather than relying on results associated with a different studied regimen.

Sources: [11] [3] [4]

How much notice is required to cancel?

The public statements conflict. Terms describe disabling auto-refill at least 48 hours before monthly processing, while treatment FAQs require 30 days’ notice before the next billing cycle. Obtain written confirmation of the deadline and effective cancellation date for your order. Stopping future renewals does not itself create a refund entitlement; the treatment pages separately describe services and processed medication as nonrefundable under stated conditions.

Sources: [9] [6]

Can I use my own pharmacy or receive treatment while traveling?

The terms restrict included prescriptions to platform-accessible pharmacies and require accepting a waiver of pharmacy choice. They also require you to be physically in the same state as your account’s shipping address when consulting a provider. Because the consulted pages do not enumerate operating states, confirm availability and travel-related consultation constraints directly rather than relying on the homepage’s nationwide description.

Sources: [9] [10]

What support is documented after enrollment?

The treatment page includes secure-portal messaging with the provider between scheduled check-ins and continuing reviews, without specifying their frequency. General contact channels include email, telephone and a form advertising a response within 24 hours. That general response promise is not a documented clinician-message turnaround or emergency service. Ask who handles side-effect questions, delivery problems and medical concerns outside the listed weekday hours.

Sources: [6] [7]

Our assessment

The Wellness Solution documents a recognizable telehealth service: assessment, independent prescribing, partner-pharmacy fulfillment, bundled charges and ongoing portal access. Its explicit compounded-medication disclosure and separation of platform responsibilities are useful. However, public documentation does not establish provider-specific clinical outcomes, the evidence for its Microdose protocol, named care partners or a product-specific $146 offer. Conflicting cancellation deadlines and qualified geographic and privacy statements further limit what the headline promises can establish. A well-prepared prospective patient would obtain the exact product and pharmacy identity, written price and supply terms, monitoring arrangements and applicable cancellation deadline before enrolling. The evidence supports describing an offered care pathway—not certifying its clinical performance or treating research on particular medicines as proof of this platform’s results.

Visit The Wellness Solution’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

The Wellness Solution Review: What Its GLP-1 Documentation Establishes—and What It Does Not

At a glance

01Start with the product, not the ingredient’s reputation

02Microdose marketing needs its own evidence

03Who provides care, and what enrollment actually requires

04Eligibility language and nationwide advertising have limits

05The $146 headline is not a product-specific quote

06Cancellation is the clearest unresolved policy conflict

07Pharmacy fulfillment and follow-up need separate scrutiny

08Privacy and support promises require their qualifiers